
|Videos|September 12, 2014
Adjuvant Capecitabine/Gemcitabine for EHCC and GBCA
Author(s)Melanie B. Thomas, MD
Melanie B. Thomas, MD, discusses the rationale of a phase II study of adjuvant capecitabine/gemcitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma.
Advertisement
Clinical Pearls
Melanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the rationale of a phase II study of adjuvant capecitabine/gemcitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma.
- Though surgery is the only curative option for patients with extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinomas (GBCA), there is still a high risk of the cancer returning.
- There remains a need for an option for these patients after surgery.
- This trial established the feasibility of adjuvant treatment in EHCC and GBCA.
More on this study > >
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































